<DOC>
	<DOCNO>NCT02453087</DOCNO>
	<brief_summary>This open-label , multicenter , Phase 1/1b study evaluate safety , tolerability , pharmacokinetics increase dos DCDS0780A participant relapse refractory B-cell non-Hodgkin 's lymphoma . In combination portion study , safety tolerability DCDS0780A combination rituximab obinutuzumab assess .</brief_summary>
	<brief_title>A Study Escalating Doses DCDS0780A Participants With Relapsed Refractory B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Life expectancy least 12 week Histologically confirm Bcell nonHodgkin 's lymphoma relapse failed respond least one prior treatment regimen suitable therapy curative intent high priority exist A clinical indication treatment determine investigator Availability archival freshly collect tumor tissue study enrollment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Fasting ( great equal [ &gt; = ] 8 hour ) glucose less equal ( &lt; = ) 160 milligram per deciliter ( mg/dL ) Participants require antidiabetic medication must stable dose regimen &gt; =4 week Adequate hematologic function without growth factor transfusion support For woman postmenopausal ( &gt; = 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use single combine contraceptive method specify protocol For men : agreement remain abstinent use condom plus additional contraceptive method specify protocol Prior use monoclonal antibody antibodydrug conjugate within 4 week Cycle 1 , Day 1 Treatment radiotherapy , chemotherapeutic agent , systemic steroid use antineoplastic agent , investigational anticancer agent within 2 week prior Cycle 1 , Day 1 Completion autologous stem cell transplant within 100 day prior Cycle 1 , Day 1 Prior allogeneic stem cell transplant Current history CNS lymphoma Current Grade great ( &gt; ) 1 toxicity ( except alopecia anorexia ) prior therapy Current Grade &gt; 1 peripheral neuropathy cause Glycosylated hemoglobin ( HbA1c ) &gt; =7.5 percent ( % ) History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) Prior irradiation lung field Clinically significant pulmonary disease Recent major surgery within 4 week prior Cycle 1 , Day 1 , superficial lymph node biopsy diagnosis Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Presence positive test result hepatitis B ( hepatitis B surface antigen [ HbsAg ] and/or total hepatitis B core antibody [ antiHBc ] ) hepatitis C ( hepatitis C virus [ HCV ] antibody ) Known history human immunodeficiency virus ( HIV ) seropositive status Women pregnant lactate intend become pregnant study Any abnormal laboratory value specify protocol Requirement exclude medication specify protocol History malignancy could affect compliance protocol interpretation result Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render participant high risk treatment complication , include inadequately control diabetes significant cardiovascular disease Known active bacterial , viral , fungal , mycobacterial , parasitic , infection ( exclude fungal infection nail bed ) study enrollment major episode infection require treatment intravenous antibiotic hospitalization ( relate completion course antibiotic ) within 4 week prior Cycle 1 , Day 1 Participants Phase 1b Stage Only : Vaccination live vaccine within 6 month Cycle 1 , Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>